Ophthalmic Imaging Systems Reports Third Quarter Financial Results

SACRAMENTO, CA--(Marketwire - November 08, 2010) - Ophthalmic Imaging Systems (OIS) (OTCBB: OISI), a leading digital imaging, image management, Electronic Medical Records (EMR) and Practice Management (PM) company, today reported financial results for the three and nine months ended September 30, 2010, and provided an update on recent corporate developments.

For the third quarter of 2010, OIS reported record net revenue of $4.9 million, up 25% or $992,000 from net revenue of $3.9 million for the third quarter of 2009, primarily due to higher product sales. Gross margin for the three months ended September 30, 2010 was 55%, compared with 58% in the prior year period, with the decline due to product mix.

Operating expenses for the third quarter of 2010 were $3.2 million, compared with $2.1 million for the third quarter of 2009. Sales and marketing expenses increased to $1.7 million compared with $959,000 in the prior year period, with the increase primarily due to expenses to introduce and support the launch of OIS EyeScan™ in international and U.S. eye care markets.

The net loss for the third quarter of 2010 was $466,788, or $0.02 per share, compared with net income of $85,656, or $0.00 per share, for the third quarter of 2009.

“We are reporting record net revenue for the quarter and nine month period with strong growth coming from both our informatics and eye imaging businesses,” said Gil Allon, Chief Executive Officer of OIS. “We continue to gain traction with our informatics solutions, due to the strength of our product and service offerings and favorable market dynamics. OIS is the only provider of a single EMR/PM, PACS and Imaging solution for ophthalmology practices, and our wholly owned subsidiary Abraxas Medical Solutions is expanding into the OB/GYN and orthopedic specialty markets with a single-platform EMR/PM and scheduling solution.

“We received a warm reception at last month’s American Academy of Ophthalmology meeting to our recently launched clinical content for OIS EMR v 4.1, a CCHIT 08-approved Ambulatory EHR. We also showcased the expanded capabilities of the OIS Symphony™ with the new Web Digital Reporter module, as well as the addition of new Symphony Link partners. These offerings build on the established position of OIS Symphony as the gold standard for eye care image management systems.

“We are pleased with early acceptance of our OIS EyeScan,” he added. “This is the only FDA-approved portable device that allows for scanning both the anterior and posterior of the eye. We recently added a seventh product module, which enables eye care professionals to capture retinal images without dilating a patient’s eye. We believe the new module further supports our market expansion opportunity beyond U.S. ophthalmologists to the approximate 35,000 domestic optometrists and eye care professionals in international markets.”

Nine Month Financial Results
For the nine months ended September 30, 2010, OIS reported record net revenue of $13.8 million, up 50% from net revenue of $9.2 million for the nine months ended September 30, 2009. The $4.6 million increase is primarily due to higher product sales. Gross margin for the nine months ended September 30, 2010 reached 57% from 53% for the first nine months in 2009, mainly due to an increase in higher-margin software revenue. Operating expenses for the nine months ended September 30, 2010 were $9.4 million, compared with $10.9 million for the comparable period last year, which included $4.4 million in impairment expense related to the debt of MediVision Medical Imaging Ltd. The net loss for the nine months ended September 30, 2010 was $1.8 million, or $0.06 per share, compared with a net loss for the nine months ended September 30, 2009 of $5.0 million, or $0.25 per share.

As of September 30, 2010, the Company had current assets of $11 million, which included $2.0 million in cash from the final installment under a June 2009 purchase agreement with U.M. AccelMed, LP completed in May 2010, and stockholders’ equity of $5.9 million.

About Ophthalmic Imaging Systems
Ophthalmic Imaging Systems (www.oisi.com) is the leading provider of ophthalmic digital imaging and informatics systems. The Company designs, develops, manufactures and markets digital imaging systems, image management and integrated EMR and PM solutions for the eye care market. With more than 25 years in the ophthalmic imaging business, the Company has consistently introduced new, innovative technologies. Through its wholly owned subsidiary, Abraxas Medical Solutions, the Company provides EMR and PM software to OB/GYN, orthopedic and primary care physicians. The Company markets and supports its products through an extensive network of dealers, distributors and direct representatives.

Statements in this press release which are not historical data are forward-looking statements which involve known and unknown risks, uncertainties, or other factors not under the Company’s control, which may cause actual results, performance, or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward-looking statements. These factors include, but are not limited to, those detailed in the Company’s periodic filings with the Securities and Exchange Commission.

 Ophthalmic Imaging Systems Selected Financial Data Condensed Consolidated Statements of Operations Three Months Ended Nine Months Ended September 30, September 30, UNAUDITED UNAUDITED UNAUDITED UNAUDITED 2010 2009 2010 2009 Net Revenue $ 4,924,881 $ 3,933,183 $ 13,818,325 $ 9,241,330 Cost of Sales 2,225,807 1,654,198 6,006,508 4,337,872 ----------- ----------- ------------ ------------ Gross Profit 2,699,074 2,278,985 7,811,817 4,903,458 Sales And Marketing 1,696,581 959,282 5,017,609 2,731,518 General And Administrative 592,416 478,484 1,694,318 1,649,391 Impairment related to the debt of MediVision - - - 4,436,187 Research and development 956,565 692,512 2,663,263 1,813,830 Research and development-related party - - - 294,014 ----------- ----------- ------------ ------------ Total Operating Expenses 3,245,562 2,130,278 9,375,190 10,924,940 ----------- ----------- ------------ ------------ Loss From Operations (546,488) 148,707 (1,563,373) (6,021,482) Other Income – Settlement - - - 1,200,000 Interest And Other Expense, Net 48,675 (60,681) (273,549) (200,332) ----------- ----------- ------------ ------------ Net Loss Before Income Taxes (497,813) 88,026 (1,836,922) (5,021,814) Income Tax Expense 12,553 (2,370) 4,019 (5,023) ----------- ----------- ------------ ------------ Net Loss (485,260) 85,656 (1,832,903) (5,026,837) ----------- ----------- ------------ ------------ Less Noncontrolling Interest’s Share (18,472) - (32,046) - Net Loss Attributable To Ophthalmic Imaging Systems $ (466,788) $ 85,656 $ (1,800,857) $ (5,026,837) =========== =========== ============ ============ Basic And Diluted Net Loss Per Share $ (0.02) $ (0.00) $ (0.06) $ (0.25) Shares Used In The Calculation Of Basic And Diluted Net Loss Per Share 30,301,686 26,500,059 28,305,828 20,289,626 Ophthalmic Imaging Systems Condensed Consolidated Balance Sheets (Unaudited) Assets September 30, 2010 December 31, 2009 ------------------ ------------------ Current assets: UNAUDITED UNAUDITED Cash and cash equivalents $ 4,789,069 $ 5,406,239 Accounts receivable, net 4,151,638 2,710,987 Inventories, net 1,831,941 991,325 Prepaid expenses and other current assets 391,664 179,451 ------------------ ------------------ Total current assets 11,164,312 9,288,002 Restricted cash - 158,213 Furniture and equipment, net of accumulated depreciation of $1,240,863 and $1,076,084 respectively 491,264 481,394 Capitalized imaging software, net of accumulated amortization of $294,413 and $168,236, respectively 210,298 336,475 Capitalized software development, net of accumulated amortization of $671,320 and $383,612, respectively 479,511 767,220 AcerMed asset purchase, net of accumulated amortization of $332,542 and $190,024, respectively 237,535 380,053 Goodwill 807,000 807,000 Customer relationship intangible assets and other intangible assets, net of accumulated amortization of $56,727 and $11,636, respectively 632,929 680,364 Prepaid financing - 22,195 Licensing rights intangible asset, net of accumulated amortization of $24,779 and $0, respectively 74,334 99,112 Other assets 9,635 17,349 ------------------ ------------------ Total assets $ 14,106,818 $ 13,037,377 ================== ================== Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 1,360,989 $ 867,672 Accounts payable – related party - 41,847 Accrued liabilities 1,529,194 1,115,902 Deferred extended warranty revenue- current portion 1,782,267 1,632,491 Customer deposits 423,614 561,245 Notes payable- current portion 1,665,527 34,048 ------------------ ------------------ Total current liabilities 6,761,591 4,253,205 Deferred extended warranty revenue, less current portion 270,979 247,231 Line of credit - 150,000 Notes payable, less current portion 1,202,775 2,946,179 ------------------ ------------------ Total liabilities 8,235,345 7,596,615 ------------------ ------------------ Commitments and contingencies Equity Ophthalmic Imaging Systems’ stockholders’ equity: Common stock, no par value, 100,000,000 shares authorized; 30,302,151 and 26,500,059 issued and outstanding at September 30, 2010 and December 31, 2009, respectively 21,715,692 20,089,592 Additional paid-in-capital 1,099,684 420,610 Accumulated deficit (17,337,027) (15,536,170) Cumulative translation adjustment (39,319) 2,241 ----------------- ----------------- Total Ophthalmic Imaging Systems’ stockholders’ equity 5,439,030 4,976,273 ----------------- ----------------- Noncontrolling interest 432,443 464,489 ----------------- ----------------- Total equity 5,871,473 5,440,762 ----------------- ----------------- Total liabilities and stockholders’ equity $ 14,106,818 $ 13,037,377 ================= =================